Comparative Study on Liver Resection Between Harmonic Scalpel Versus Crush-clamping Method

NCT ID: NCT02213692

Last Updated: 2016-02-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-05-31

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Blood loss during liver resection significantly associates with short term operative outcome. The median blood loss during partial liver resection is 700-1200ml in high-volume centers. Conventional method (crush-clamp) has been a standard technique for liver transection. Technique advances related to liver transection have contributed to reduction in blood loss. Several studies have showed that Harmonic Scalpel in liver resection is safe and easy to use. A nonrandomized study showed use of the Harmonic Scalpel was associated with decreased operative time, blood loss and transfusion requirement, and an increased incidence of postoperative bile leakage. However, no randomized study has compared the difference between liver resection using traditional technology and harmonic Scalpel. The objective of this prospective randomized study is to compare the safety and efficacy of liver resection using the harmonic scalpel device with the "crush-clamp" technique in respect to blood loss, liver transection time, hepatic hilum clamping time, hospital stay and postoperative complications.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Blood loss during liver resection significantly associates with short term operative outcome. The median blood loss during partial liver resection is 700-1200ml in high-volume centers. Conventional method (crush-clamp) has been a standard technique for liver transection. Technique advances related to liver transection have contributed to reduction in blood loss. Several studies have showed that Harmonic Scalpel in liver resection is safe and easy to use. A nonrandomized study showed use of the Harmonic Scalpel was associated with decreased operative time, blood loss and transfusion requirement, and an increased incidence of postoperative bile leakage. However, no randomized study has compared the difference between liver resection using traditional technology and harmonic Scalpel. The objective of this prospective randomized study is to compare the safety and efficacy of liver resection using the harmonic scalpel device with the "crush-clamp" technique in respect to blood loss, liver transection time, hepatic hilum clamping time, hospital stay and postoperative complications. All patients submitted to liver resection are randomized into two groups: those submitted to liver resection with the use of "crush-clamp" technique. (group Α) and those with the use of the Harmonic Scalpel device (group Β).

Crush-clamping Method (group A) :Patients submitted to liver resection with the use of "crush-clamping" technique.

Device: Liver parenchymal is crushed by surgeon's fingers or basic surgical clamps to isolate small vessels and biliary radicals, and then divided by suture ligation, electrocautery, or vascular clips.

Harmonic Scalpel (group B) :Patients submitted to liver resection with the use of the Harmonic Scalpel device.Device: liver parenchymal transection is transected by harmonic scalpel, and small vessels and biliary radicals (\<3mm) is also divided by harmonic scalpel. Vessels and biliary radicals (≥ 3mm) were divided by suture ligation, electrocautery, or vascular clips.

Primary Outcome Measures:

Blood loss during operation \[an expected average of 3 hours\] operation\]\[Designated as safety issue: Yes\] Postoperative complications including bile leakage, bleeding, morbidity, injured Liver function \[Time Frame: participants will be followed for the duration of hospital stay, an expected average of 8 days\] \[Designated as safety issue: Yes\]

Secondary Outcome Measures:

Transection time from Mark of the cutting edge to finish disposed of the cutting edge \[Designated as safety issue: No\] Hepatic hilar clamping time (Pringle's method) \[the duration of clamping of hepatic hilar\] \[Designated as safety issue: No\] Hospital stay \[participants will be followed for the duration of hospital stay, an expected average of 8 days\] \[Designated as safety issue: No\] Enrollment: 128 Study Start Date: June 2014 Study Completion Date: May 2015 Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)

Eligibility:

Genders Eligible for Study: Both Accepts Healthy Volunteers: No

Criteria:

Inclusion Criteria:

1. Age ≥18y, and ≤80y;
2. No history of liver resection and radiotherapy
3. Liver function: Child A with a normal prothrombin time (\<13 seconds) and international normalized ratio (INR )(\<1.15);
4. Extent of resection ≥2 segment or diameter of tumor (single nodule) ≥ 8cm or cumulative diameter of tumor (multiple nodule) ≥ 8cm; Eligible patients will be stratified by resection in left lobe or right lobe.
5. No tumor thrombosis in main trunk or right and left branch of portal vein or major hepatic vein.

Exclusion Criteria:

1. Recurrent liver tumor; or simultaneous resection of other organs except gallbladder
2. Prothrombin time \> 13seconds;
3. Blood platelets count (BPC) \< 60\*109
4. Moderate and severe of esophageal varices detected by CT or MRI
5. Diameter of portal vein \> 14mm (color ultrasound)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatic Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Crush-clamping Method (group A)

Liver parenchymal is crushed by surgeon's fingers or basic surgical clamps to isolate small vessels and biliary radicals, and then divided by suture ligation, electrocautery, or vascular clips.

No interventions assigned to this group

Harmonic Scalpel Method (group B)

Liver parenchymal transection is transected by harmonic scalpel, and small vessels and biliary radicals (\<3mm) is also divided by harmonic scalpel. Vessels and biliary radicals (≥ 3mm) were divided by suture ligation, electrocautery, or vascular clips.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥18y, and ≤80y;
2. No history of liver resection and radiotherapy
3. Liver function: Child A with a normal prothrombin time (\<13 seconds) and INR (1.15);
4. Extent of resection ≥2 segment or diameter of tumor (single nodule) ≥ 8cm or cumulative diameter of tumor (multiple nodule) ≥ 8cm; Eligible patients will be stratified by resection in left lobe or right lobe.
5. No tumor thrombosis in main trunk or right and left branch of portal vein or major hepatic vein.

Exclusion Criteria

1. Recurrent liver tumor; or simultaneous resection of other organs except gallbladder
2. Prothrombin time \> 13S;
3. Blood platelets count (BPC) \< 60x109
4. Moderate and severe of esophageal varices detected by CT or MRI
5. Diameter of portal vein \> 14mm (color ultrasound)
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hui-Chuan Sun

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hui-Chuan Sun

Professor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hui Chuan Sun, Professor

Role: STUDY_CHAIR

Fudan University

Jia Fan, Professor

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Jian Zhou, Professor

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Shuang Jian Qiu, Professor

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Guo Ming Shi, Asso. Prof.

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Qing Hai Ye, Professor

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Lu Wang, Professor

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Xiao Wu Huang, Professor

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Ning Ren, Professor

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Jing Xian Yu, Nurse

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Yang Xu, Asso. Prof.

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Ying Hong Shi, Asso. Prof.

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Xiao Ying Wang, Asso. Prof

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Jian Sun, Asso. Prof.

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Zheng Wang, Asso. Prof.

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Yong Sheng Xiao, Asso. Prof.

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Pei Chen, Asso. Prof.

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Cheng Huang, Asso. Prof.

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Ying Hao Shen, Asso. Prof.

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Zhongshan Hospital of Fudan University

Shanghai, Shanghai Municipality, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

D2014-051

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.